Evangleos Rizos
Associate Professor, Pathophysiology
Ev.Rizos@euc.ac.cy
22559410
School of Medicine
Medicine
Academic Qualifications
| Qualification | Year | Awarding Institution | Department | Thesis title (Optional Entry) |
| Medical Degree (MD) | 1993 | University of Athens | School of Medicine | |
| PhD | 2005 | University of Ioannina | School of Medicine | "The effect of drugs in the enzyme PAF-acetylhydrolase (PAFAH/LpPLA2) in serum and in lipoproteins", mention: summa cum laude |
| Specialization (Internal Medicine) | 2001 | University of Ioannina | University hospital of Ioannina | |
| Specialization (Diabetology) | 2010 | General hospital of Nikaia, Athens | Diabetes clinic |
Employment History
| Period of employment | Employer | Location | Position | |
| From | To | |||
| 2002 | present | University Hospital of Ioannina, Greece | Department of Internal Medicine, University Hospital of Ioannina, Greece | Consultant in Internal Medicine |
| 2010 | present | University Hospital of Ioannina, Greece. | Diabetes Clinic, University Hospital of Ioannina, Greece. | Head of the outpatient Diabetes Clinic |
| 2017 | 2017 | Medical School, University of Cyprus. | Medical School, University of Cyprus. | Assistant Professor in Internal Medicine (visiting, part time) |
Publications
| Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
| 2019 | The combination of prediabetes with atherogenic dyslipidemia or obesity increase the risk of statin-induced diabetes. | Barkas F, Elisaf M, Liberopoulos E, Liamis G, Ntzani EEN, Rizos EC. | Journal of Cardiology | In press | |
| 2019 | Is mesenteric panniculitis a sign for latent autoimmune diabetes in adults? | Rizos EC, Panagiotopoulou T, Liberopoulos E, Elisaf M, Tsili AC, Argyropoulou MA, Tigas SK. | AACE Clinical Case Reports | In press | |
| 2019 | Bridging the treatment gap in patients at 'extreme' cardiovascular risk: Evidence from a lipid clinic. | Barkas F, Elisaf M, Rizos EC, Liberopoulos E. | Atherosclerosis. | Feb;281 | 216-218 |
| 2018 | Educational strategies to train health care professionals across the education continuum on the process of frailty prevention and frailty management: a systematic review. | Windhaber T, Koula ML, Ntzani E, Velivasi A, Rizos E, Doumas MT, Pappas EE, Onder G, Vetrano DL, Roudriguez Laso A, Roudriguez Manjas L, Illario M, Roller-Wirnsberger RE; ADVANTAGE JA WP8 group. | Aging Clin Exp Res. | Dec;30(12) | 1409-1415. |
| 2017 | Kernel-based adaptive learning improves accuracy of glucose predictive modelling in type 1 diabetes: A proof-of-concept study. | Georga EI, Principe JC, Rizos EC, Fotiadis DI. | Conf Proc IEEE Eng Med Biol Soc. | 2017 Jul;2017 | 2765-2768 |
| 2012 | Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. | Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. | JAMA. | Sep 12;308(10) | 1024-1033. |
| 2014 | Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial. | Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP. | Diabetes Care. | Sep;37(9) | 2522-2532. |
| 2011 | Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents. | Rizos ΕC, Salanti G, Kontoyiannis DP, Ioannidis JP. | J Clin Epidemiol | Aug 64(8) | 830-842. |
| 2014 | ω-3 Fatty acids and lutein + zeaxanthin supplementation for the prevention of cardiovascular disease. | Rizos EC, Ntzani EE. | JAMA Intern Med. | May;174(5) | 771-772. |
| 2015 | Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. | Liakos A, Athanasiadou E, Mainou M, Bekiari E, Haidich AB, Rizos EC, Tsapas A. | Ann Intern Med. | Aug 4;163(3) | 241-242 |
Exhibitions
Research Projects
| Date | Title | Funded by | Project Role* |
| 2018 –2021 | Health Study of Epirus. | European funded ESPA (ΕΣΠΑ), Operational program “Epirus” 2014-2020. | Investigator |
| 2018 –2019 | Air Quality and Health-related Outcomes: An Evidence-based System for Education and Awareness | European Social Fund & Youth Employment Initiative; Operational programme "Human Resources Development, Education and Life Lifelong Learning; Action: “Supporting research: emphasis on junior researchers”. | Investigator. |
| 2013 - 2016 | Credits for Health (C4H): ‘Credits-based, people-centric approach for the adoption of healthy life-styles and balanced Mediterranean diet in the frame of social participation and innovation for health promotion’. | EU funded research project | Investigator |
| 2017-2018 | 1245.72 (EASE-3): Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus. | Boehringer | Principal Investigator |
| 2017-2018 | OBS13780 (DUNE): Multinational, Prospective, Observational Study to Assess the Unmet Medical Needs associated with Basal Insulin Use in Patients with Type 2 Diabetes Mellitus (T2DM) Newly or Recently Initiated Basal Insulin Treatment. | Sanofi | Principal investigator |
| 2017-2018 | 1218.149: randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes Mellitus patients with insufficient glycaemic control. | Boehringer | Principal investigator |
| 2014-2019 | 1245.78 (CAROLINA): double blind, multicenter, randomized control trial (RCT) for the assessment of linagliptin on cardiovascular outcomes in high-risk type 2 diabetes patients. | Boehringer | Principal Investigator |
| 2017-2020 | 210224: “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of ertugliflozin (PF-04971729) as Compared with Placebo on the Occurrence of Cardiovascular Events in subjects with Type 2 Diabetes Mellitus and Established vascular disease” | Pfizer | Co-investigator |
| 2018-2021 | Sotagliflozin: randomized double-blind, placebo controlled parallel-group, multicenter study to demonstrate the effects of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes, cardiovascular risk factors and moderately impaired renal function. | Sanofi | Co-investigator |
| 2006 | “Evaluation of guidelines in electronic form for the region of Epirus”, for the European research project “Building knowledge driven and dynamically adaptive networked communities within European healthcare systems -COCOON-“. | European research project “Building knowledge driven and dynamically adaptive networked communities within European healthcare systems -COCOON-“. | Investigator |
Academic Consulting Services/Councils/Boards/Editorial Committees
| Period | Organization | Title of Position or Service | Key Activities |
| 2011-present | Current Vascular Pharmacology | Member of the Editorial Board | Member of the Editorial Board |
| 2016-present | World Journal of Hypertension | Member of the Editorial Board | Member of the Editorial Board |
| 2012-present | Journal of Single Cell Genomics & Proteomics | Member of the Editorial Board | Member of the Editorial Board |
| 2017 | NovoNordisk | Member of the Advisory Board | Member of the Advisory Board for “Latest data for diabetes type 1 management, Greece”. |
| 2016 | NovoNordisk | Member of the Advisory Board | Member of the Advisory Board for “Cardiovascular safety of Liraglutide: LEADER study, Greece”. |
Awards/International Recognition
| Date | Title | Awarded by: |
| 2017 | Barkas F, Liberopoulos E, Sferopoulos D, Klouras E, Liontos A, Elisaf M, Rizos E. Which metabolic parameters are related to the increased risk for diabetes development in statin-treated patients. | 7th congress of the working parties of Hellenic Atherosclerosis Society, 2017, Athens. |
| 2016 | Klouras E, Barkas F, Elisaf M, Liberopoulos E, Liamis G, Rizos E. Statin therapy with or without ezetimibe and the progression to diabetes. 1st prize. | 6ο Panhellenic Congress, Institute of Study, Research & Education for Diabetes Mellitus and Metabolic Diseases, 2016. |
Other Achievements
| 69 PUBLICATIONS (international peer review journals) | Author
CITATIONS (up to Dec 2018)
|
| 1. Sotagliflozin/Sanofi: Co-investigator for this randomized double-blind, placebo controlled parallel-group, multicenter study to demonstrate the effects of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes, cardiovascular risk factors and moderately impaired renal function. 2. EGNATIA: Co-investigator for Streptococcus pneumonia serotypes in hospitalized adults with radiological confirmed community acquired pneumonia. 3. SUSTAIN 7: Co-investigator for this Phase III, Randomised, Double Blind, Parallel Group study to assess the efficacy and safety of semaglutide compared to dulaglutide in addition to metformin in type 2 diabetic patients. 4. ONSET 9: Co-investigator for this Phase III, Randomised, Double Blind, Parallel Group study to assess the efficacy and safety of faster acting insulin aspart compared to novorapid in addition to degludec with or without metformin in adults type 2 diabetic patients. 5. MK-8835-004/B1521021: Co-investigator for this Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group study to assess cardiovascular outcomes following treatment with ertugliflozin in subjects with type 2 diabetes and established vascular disease. 6. NN9924-4280 (Pioneer 8): Co-investigator for this Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Oral Semaglutide as Adjunctive to Insulin Therapy. 7. Boehringer 1245.72 (EASE-3): Principal Investigator for this Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus. 8. Mediterranean Group for the Study of Diabetes (MGSD): Co-investigator for the Multicentre study to genetically detect monogenic diabetes among patients in the Mediterranean region suspected to have atypical non-autoimmune diabetes, Mediterranean Group for the Study of Diabetes (MGSD). 9. EFC11570 - ODYSSEY: Co-investigator for this Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome. 10. GLP116174 (HARMONY): Co-investigator for this “Long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events (MACE) in patients with Type 2 diabetes mellitus”, Harmony Outcomes Trial. 11. OBS13780 (DUNE): Principal investigator for this Multinational, Prospective, Observational Study to Assess the Unmet Medical Needs associated with Basal Insulin Use in Patients with Type 2 Diabetes Mellitus (T2DM) Newly or Recently Initiated Basal Insulin Treatment. 12. AGREEMENT - DIREG_L_06565: Principal investigator for this epidemiologic study to register the current treatment of type 2 diabetic patients in Greece in order to define the current clinical approach. 13. Boehringer 1218.149: Principal investigator for this 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes Mellitus patients with insufficient glycaemic control. 14. XALIA-XARELTO: Co-investigator for Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism 15. AMG 145 - AMGEN: Co-investigator for this Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease 16. FOURIER: Co-investigator for: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk 17. Menarini: Co-investigator for this Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout 18. Pfizer 210224: Co-investigator for this “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of ertugliflozin (PF-04971729) as Compared with Placebo on the Occurrence of Cardiovascular Events in subjects with Type 2 Diabetes Mellitus and Established vascular disease” 19. Boehringer 1245.78 (CAROLINA): Principal Investigator for this double blind, multicenter, randomized control trial (RCT) for the assessment of linagliptin on cardiovascular outcomes in high-risk type 2 diabetes patients. 20. EXAMINE: Co-investigator for this double blind, multicenter, randomized control trial (RCT) for the assessment of alogliptin on cardiovascular outcomes in acute post-MI type 2 diabetes patients. 21. ONTARGET: Co-investigator for this double blind, multicenter, randomized control trial (RCT) for the efficacy of ramipril and/or telmisartan in the prevention of heart disease in high-risk patients. 22. TRANSCEND: Co-investigator for this double blind, multicenter, randomized control trial (RCT) for the efficacy of telmisartan in the prevention of heart disease in high-risk patients with intolerance to the angiotensin converting enzyme (ACE) inhibitors. 23. CHARISMA: Co-investigator for this phase III trial for the efficacy of clopidogrel in the prevention of atherothrombosis and myocardial infarction in high-risk patients. 24. AVANDARYL: Co-investigator for this double blind, multicenter, parallel group trial to compare the efficacy and safety of fixed dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naive subjects with type 2 diabetes mellitus. 25. NIS-CEU-DUM-2008/1 EURIKA: Co-investigator for the epidemiology of cardiovascular risk in European countries. Prevention and management in the usual clinical practice. 26. MK-3577-009-00: Co-investigator for this phase ΙΙα, multicentre, placebo controlled double-blind study, for the evaluation of safety and efficacy of mk-3577 for patients with diabetes type 2, with poor glycemic control. 27. CLMF237AGR01/09-07.2009 (LESS): Co-investigator for this multicentre study for the evaluation of compliance of type 2 diabetic patients on treatment with metformin and vildagliptin (galvus) compared to patients on treatment with fixed combination of metformin/vildagliptin (eucreas). 28. REACH REGUSTR - C8903: Co-investigator for this multicenter, prospective observational study for high-risk patients for atherothrombotic complications. 29. L-TAP: Co-investigator for this multicenter, prospective observational study for the proportion of the dyslipidemic patients under treatment who achieve the goals of the NCEP for the low density lipoprotein (LDL) cholesterol. 30. ATTEMPT: Co-investigator for this multicenter, prospective, ramdomized control trial (RCT) for the efficacy of atorvastatin in patients with the metabolic syndrome. |
INVESTIGATOR FOR CLINICAL TRIALS |
| 1. European Centre for Disease Prevention and Control (ECDC) expert (from 2015). 2. Diabetes & Cardiovascular disease - D&CVD- EASD study group (from 2012). 3. Hellenic Diabetes Association (from 2010). 4. Study group for Diabetes & Heart of the Hellenic Diabetes Association (from 2015). 5. Hellenic Atherosclerosis Society (HAS), (from 2003). 6. Study group of the Hellenic Atherosclerosis Society (HAS) for the epidemiology and prevention of atherosclerosis (2013-2015). 7. Institute for Research and Education for Diabetes Mellitus and Metabolic Syndromes, Greece (member of the Executive Board 2010-2013). 8. European Association for the Study of Diabetes - EASD (2011-2013). 9. Study group of the Hellenic Atherosclerosis Society (HAS) for the Metabolic Syndrome (2011-2012). | MEMBER OF MEDICAL/SCIENTIFIC SOCIETIES |
| 29 SCIENTIFIC ANNOUNCEMENTS in International congresses | Author |
| 34 SCIENTIFIC ANNOUNCEMENT in national congresses | Author |
| 1. European Journal of Clinical Investigation (2018) 2. Diabetes Obesity & Metabolism (2018, 2017,2016,2015) 3. Expert Opinion on Drug Safety (2015) 4. Case Reports in Vascular Medicine (2015) 5. BMC public health (2015, 2014, 2013) 6. BMC endocrinology (2014, 2013, 2012) 7. Medicine (2014) 8. JAMA (2013) 9. J Acad Nutr Diet (2013) 10. Arch Med Sci (2012) 11. Curr Med Res Opin (2012) 12. Drug Saf (2012) 13. Expert Opin Pharmacother (2011) 14. The Open Cardiovasc Med J (2009) | REVIEWER (for submitted manuscripts in PubMed indexed journals) |